» Articles » PMID: 3062845

Effect of Glicentin-related Peptides Upon the Secretion of Insulin and Glucagon in the Canine Pancreas

Overview
Specialty General Medicine
Date 1988 Jun 1
PMID 3062845
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

In order to clarify responses of the endocrine pancreas to glicentin, four glicentin-related peptides were investigated in a local circulation preparation of the canine pancreas. These peptides were administered in a dosage of 200 pmole for 10 min into the pancreaticoduodenal artery under the continuous infusion of 0.5% arginine solution. In a group of six dogs, the administration of glicentin-related pancreatic peptide (GRPP) and glicentin 1-16 resulted in an increase in plasma insulin (IRI) and a decrease in plasma glucagon (IRG). In the other group of six dogs, the administration of glicentin 62-69 induced an increase in plasma IRI and a decrease in plasma IRG. Following the successive infusion of oxyntomodulin, both plasma IRI and IRG increased slightly. Porcine glucagon administered at the end of each experiment exerted a rise in blood glucose and plasma IRI in addition to an increase in plasma IRG. In comparison of the maximal responses of plasma IRI and IRG to these glicentin-related peptides, the administration of glicentin 1-16, 62-69 or GRPP elicited an increase in plasma IRI and a decrease in plasma IRG. In contrast, oxyntomodulin and glucagon increased both plasma IRI and IRG. The present study indicates that glicentin-related peptides, both the N- and C-terminal portions, affect the endocrine function of the pancreas and suggests that glicentin released by nutrient ingestion plays an important role in the enteroinsular axis.

Citing Articles

Is glucose-induced hypersecretion of glicentin after the revision surgery using Roux-en-Y gastric bypass related to improved glycemic control due to insulin hypersecretion in a type 2 diabetes patient without diabetes remission after laparoscopic....

Yamamoto Y, Sekine O, Ito-Kobayashi J, Nishida A, Togawa T, Ozamoto Y J Diabetes Investig. 2024; 16(2):343-347.

PMID: 39556486 PMC: 11786166. DOI: 10.1111/jdi.14325.


The Enigmatic N-Terminal Domain of Proglucagon; A Historical Perspective.

Conlon J Front Endocrinol (Lausanne). 2021; 12:683089.

PMID: 34177808 PMC: 8226317. DOI: 10.3389/fendo.2021.683089.


Proglucagon-Derived Peptides as Therapeutics.

Lafferty R, Oharte F, Irwin N, Gault V, Flatt P Front Endocrinol (Lausanne). 2021; 12:689678.

PMID: 34093449 PMC: 8171296. DOI: 10.3389/fendo.2021.689678.


Glucagon Control on Food Intake and Energy Balance.

Al-Massadi O, Ferno J, Dieguez C, Nogueiras R, Quinones M Int J Mol Sci. 2019; 20(16).

PMID: 31405212 PMC: 6719123. DOI: 10.3390/ijms20163905.


Insights on glicentin, a promising peptide of the proglucagon family.

Raffort J, Lareyre F, Massalou D, Fenichel P, Panaia-Ferrari P, Chinetti G Biochem Med (Zagreb). 2017; 27(2):308-324.

PMID: 28736498 PMC: 5508206. DOI: 10.11613/BM.2017.034.